查看购物车
  • Traditional Chinese
  • English
封面
市场调查报告书
商品编码
1638749

2024年至2032年鼻腔给药技术市场机会、成长动力、产业趋势分析与预测

Nasal Drug Delivery Technology Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2024 to 2032
出版日期: | 出版商: Global Market Insights Inc. | 英文 150 Pages | 商品交期: 2-3个工作天内

价格
简介目录

2023年，全球鼻腔给药技术市场估值达719亿美元，预计2024年至2032年复合年增长率为6.8%。这种方法以其起效快、对治疗呼吸系统疾病、疼痛管理和一些神经系统疾病非常有效而闻名。

市场按类型分为喷雾剂、滴剂和液体剂、凝胶剂和粉末剂，其中鼻喷雾剂的收入在2023 年领先，达到308 亿美元。紧急情况和管理中特别有益过敏、呼吸问题和急性病症。呼吸系统疾病、气喘和过敏症的日益流行刺激了对鼻喷剂的需求，鼻喷剂广泛用于输送抗组织胺、皮质类固醇和减充血剂等药物。

根据容器类型，市场分为加压容器和非加压容器，其中非加压容器占最大份额，2023年将占收入的82.2%。依从性，特别是在慢性病照护。它们的多功能性适用于各种製剂，例如液体和悬浮液，扩大了适用于不同条件的鼻用产品的范围，包括抗组织胺和盐水溶液。

市场范围
开始年份 2023年
预测年份 2024-2032
起始值 719 亿美元
预测值 1,295 亿美元
复合年增长率 6.8%

到 2023 年，美国鼻腔给药技术市场价值将达到 300 亿美元，预计在预测期内将以 6.9% 的复合年增长率成长。由于过敏性疾病、气喘和呼吸系统疾病的发生率很高，美国市场对鼻腔给药系统的采用激增，该系统因其快速和有针对性的作用而受到重视，这对于有效的呼吸系统疾病管理至关重要。这项需求凸显了鼻腔输送系统在美国医疗保健中日益重要的角色。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

  • 产业生态系统分析
  • 产业影响力
    • 成长动力
      • 对非侵入性给药系统的需求增加
      • 呼吸系统疾病盛行率上升
      • 技术和配方的进步
    • 产业陷阱与挑战
      • 某些药物的市场接受度有限
      • 监管挑战和审批流程
  • 成长潜力分析
  • 监管环境
  • 技术景观
  • 未来市场趋势
  • 差距分析
  • 管道分析
  • 波特的分析
  • PESTEL分析

第 4 章：竞争格局

  • 介绍
  • 公司市占率分析
  • 公司矩阵分析
  • 主要市场参与者的竞争分析
  • 竞争定位矩阵
  • 战略仪表板

第 5 章：市场估计与预测：按产品类型，2021 - 2032 年

  • 主要趋势
  • 喷雾剂
  • 滴剂和液体
  • 凝胶
  • 粉末

第 6 章：市场估计与预测：按货柜类型，2021 - 2032 年

  • 主要趋势
  • 加压容器
  • 非加压容器

第 7 章：市场估计与预测：按应用分类，2021 - 2032

  • 主要趋势
  • 鼻塞
  • 鼻炎
  • 气喘
  • 疫苗接种
  • 其他应用

第 8 章：市场估计与预测：按配销通路，2021 - 2032 年

  • 主要趋势
  • 医院药房
  • 零售药局
  • 电子商务

第 9 章：市场估计与预测：按最终用途，2021 - 2032 年

  • 主要趋势
  • 医院
  • 诊所
  • 家庭护理设置
  • 其他最终用户

第 10 章：市场估计与预测：按地区，2021 - 2032

  • 主要趋势
  • 北美洲
    • 我们
    • 加拿大
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 西班牙
    • 义大利
    • 荷兰
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 澳洲
    • 韩国
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿联酋

第 11 章：公司简介

  • Aegis Therapeutics
  • AptarGroup
  • Boehringer Ingelheim
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline
  • Horizon Therapeutics
  • Johnson & Johnson
  • Merck
  • Nasal Technologies
  • Neuralstem
  • Pfizer
  • Regeneron Pharmaceuticals
  • Takeda Pharmaceutical Company
  • XenoPort
简介目录
Product Code: 12155

The Global Nasal Drug Delivery Technology Market reached a valuation of USD 71.9 billion in 2023 and is projected to expand at a CAGR of 6.8% from 2024 to 2032. Nasal drug delivery involves administering medications through the nasal cavity, enabling rapid absorption into the bloodstream through the nasal mucosa. This method is known for its quick onset highly effective for treating respiratory conditions, pain management, and some neurological disorders.

The market is segmented by type into sprays, drops and liquids, gels, and powders, with nasal sprays leading in revenue at USD 30.8 billion in 2023. Nasal sprays enable fast absorption, offering quick relief, which is especially beneficial in emergencies and for managing allergies, respiratory issues, and acute conditions. The growing prevalence of respiratory disorders, asthma, and allergies has fueled demand for nasal sprays, widely used to deliver medications like antihistamines, corticosteroids, and decongestants.

Based on container type, the market is divided into pressurized and non-pressurized containers, with non-pressurized containers holding the largest share, at 82.2% of revenue in 2023. Non-pressurized containers are user-friendly and ideal for self-administration, supporting consistent treatment adherence, especially in chronic care. Their versatility accommodates various formulations, such as liquids and suspensions, broadening the range of nasal products available for different conditions, including antihistamines and saline solutions.

Market Scope
Start Year2023
Forecast Year2024-2032
Start Value$71.9 Billion
Forecast Value$129.5 Billion
CAGR6.8%

The U.S. nasal drug delivery technology market was valued at USD 30 billion in 2023 and is expected to grow at a 6.9% CAGR over the forecast period. With a high prevalence of allergic conditions, asthma, and respiratory diseases, the U.S. market is seeing a surge in the adoption of nasal drug delivery systems, valued for their rapid and targeted action, crucial for effective respiratory condition management. This demand highlights the increasing role of nasal delivery systems in U.S. healthcare.

Table of Contents

Chapter 1 Methodology & Scope

  • 1.1 Market scope & definitions
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Base estimates & calculations
    • 1.3.1 Base year calculation
    • 1.3.2 Key trends for market estimation
  • 1.4 Forecast model
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
    • 1.5.2 Data mining sources

Chapter 2 Executive Summary

  • 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Increased demand for non-invasive drug delivery systems
      • 3.2.1.2 Rising prevalence of respiratory disorders
      • 3.2.1.3 Advancements in technology and formulations
    • 3.2.2 Industry pitfalls & challenges
      • 3.2.2.1 Limited market acceptance for some drugs
      • 3.2.2.2 Regulatory challenges and approval processes
  • 3.3 Growth potential analysis
  • 3.4 Regulatory landscape
  • 3.5 Technological landscape
  • 3.6 Future market trends
  • 3.7 Gap analysis
  • 3.8 Pipeline analysis
  • 3.9 Porter's analysis
  • 3.10 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

  • 4.1 Introduction
  • 4.2 Company market share analysis
  • 4.3 Company matrix analysis
  • 4.4 Competitive analysis of major market players
  • 4.5 Competitive positioning matrix
  • 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product Type, 2021 - 2032 ($ Mn)

  • 5.1 Key trends
  • 5.2 Sprays
  • 5.3 Drops and liquids
  • 5.4 Gels
  • 5.5 Powders

Chapter 6 Market Estimates and Forecast, By Container Type, 2021 - 2032 ($ Mn)

  • 6.1 Key trends
  • 6.2 Pressurized containers
  • 6.3 Non-pressurized containers

Chapter 7 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

  • 7.1 Key trends
  • 7.2 Nasal congestion
  • 7.3 Rhinitis
  • 7.4 Asthma
  • 7.5 Vaccination
  • 7.6 Other applications

Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

  • 8.1 Key trends
  • 8.2 Hospital pharmacies
  • 8.3 Retail pharmacies
  • 8.4 E-commerce

Chapter 9 Market Estimates and Forecast, By End Use, 2021 - 2032 ($ Mn)

  • 9.1 Key trends
  • 9.2 Hospitals
  • 9.3 Clinics
  • 9.4 Homecare settings
  • 9.5 Other end users

Chapter 10 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

  • 10.1 Key trends
  • 10.2 North America
    • 10.2.1 U.S.
    • 10.2.2 Canada
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 France
    • 10.3.4 Spain
    • 10.3.5 Italy
    • 10.3.6 Netherlands
  • 10.4 Asia Pacific
    • 10.4.1 China
    • 10.4.2 Japan
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 South Korea
  • 10.5 Latin America
    • 10.5.1 Brazil
    • 10.5.2 Mexico
    • 10.5.3 Argentina
  • 10.6 Middle East and Africa
    • 10.6.1 South Africa
    • 10.6.2 Saudi Arabia
    • 10.6.3 UAE

Chapter 11 Company Profiles

  • 11.1 Aegis Therapeutics
  • 11.2 AptarGroup
  • 11.3 Boehringer Ingelheim
  • 11.4 Eli Lilly and Company
  • 11.5 F. Hoffmann-La Roche AG
  • 11.6 GlaxoSmithKline
  • 11.7 Horizon Therapeutics
  • 11.8 Johnson & Johnson
  • 11.9 Merck
  • 11.10 Nasal Technologies
  • 11.11 Neuralstem
  • 11.12 Pfizer
  • 11.13 Regeneron Pharmaceuticals
  • 11.14 Takeda Pharmaceutical Company
  • 11.15 XenoPort